Investing.com - Passage Bio reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations.
Passage Bio announced earnings per share of $-0.49 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.78 on revenue of $0.
Passage Bio shares are down 4.96% from the beginning of the year, still down 84.96% from its 52 week high of $8.91 set on November 10, 2021.
Passage Bio shares gained 11.67% in intra-day trade following the report.
Passage Bio follows other major Healthcare sector earnings this month
Passage Bio's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar